These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2730286)

  • 1. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Jan; 322(1):25-9. PubMed ID: 2730286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor inhibiting [1,2-bis(difluorophenyl)ethylenediamine]dichloroplatinum (II) complexes, I: Synthesis.
    Müller R; Schickaneder E; Jennerwein M; Reile H; Spruss T; Engel J; Schönenberger H
    Arch Pharm (Weinheim); 1991 Feb; 324(2):115-20. PubMed ID: 1854235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
    Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
    Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the conformational influences on the estrogenic activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes, II: Synthesis and studies on the estrogenic activity of cis- and trans[bis(2,6-dichloro-4-hydroxybenzylamine)]dihaloplatinum(II)-c omplexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1994 Dec; 327(12):763-9. PubMed ID: 7872853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
    Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
    J Cancer Res Clin Oncol; 1992; 118(3):201-8. PubMed ID: 1548285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
    Spruss T; Gust R; Müller R; Engel J; Schönenberger H
    Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, conformational studies, and investigations on the estrogen receptor binding of [R/S-1-(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]platinum(II) complexes.
    Gust R; Lubczyk V; Schmidt K; Shihada U
    Arch Pharm (Weinheim); 2001 Mar; 334(3):93-100. PubMed ID: 11315340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
    Gust R; Karl J; Faderl M; Schönenberger H
    Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.
    Müller R; Gust R; Bernhardt G; Keller C; Schönenberger H; Seeber S; Osieka R; Eastman A; Jennerwein M
    J Cancer Res Clin Oncol; 1990; 116(3):237-44. PubMed ID: 2370248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
    Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
    J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The antineoplastic action of o-substituted [1,2-bis(4-hydroxyphenyl)-ethylenediamine]dichloroplatinum (II) complexes and their methylethers].
    Karl J; Schönenberger H
    Arch Pharm (Weinheim); 1988 Jul; 321(7):405-10. PubMed ID: 3219056
    [No Abstract]   [Full Text] [Related]  

  • 16. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.
    Bernhardt G; Gust R; Reile H; vom Orde HD; Müller R; Keller C; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
    J Cancer Res Clin Oncol; 1992; 118(3):209-15. PubMed ID: 1548286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antitumor activity of [1,2-bis(4-fluorophenyl)ethylenediamine][dicarboxylato]platinum(II) complexes.
    Gust R; Krauser R; Schmid B; Schönenberger H
    Arch Pharm (Weinheim); 1998 Jan; 331(1):27-35. PubMed ID: 9507699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the configurational and conformational influences on the hormonal activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes. 1. Synthesis, estradiol receptor affinity, and estrogenic activity of diastereomeric [N-alkyl- and N,N'-dialkyl-1,2- bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 1995 Jun; 38(12):2070-9. PubMed ID: 7783138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammary tumor inhibiting [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, III: Relationship between structure and estrogenic activity of the diamine ligands, their sulfatoplatinum(II) and diiodoplatinum(II) complexes.
    Gust R; Schönenberger H
    Arch Pharm (Weinheim); 1993 Jul; 326(7):405-13. PubMed ID: 8357303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.